RE: MalachiWed 20:08
I have seen a number of interviews & analyst presentations where AN is asked about the competition. He has always said that Parsortix can complement and enhance their services and stressed that he wants to work with them.
Sorry it’s a bit long, but this is AN’s verbatim answer to a competition related question, that the Proactive interviewer asked during the interview he gave on the day AGL received FDA approval.
“ These companies are focused on the same market area, which is liquid biopsy, but none of them are focused on recovering intact living cancer cells which are involved in spreading the disease.
These companies work with fragments of dead cells called circulating tumour DN. It only enables the investigation of DNA and actually, because the cells dead, it really gives a retrospective view. If you can get an intact cancer cell, particularly one that's in the bloodstream, spreading the disease part of the metastatic process, you've got the best possible sample for analysis and it's the closest proxy to the existing standard of care tissue biopsy. And you can look at DNA, RNA, protein expression and you can look at the actual cell. So you can look at the morphology of the cell and investigators with all number of different and laboratory techniques. So it provides a complete picture.
But the other critical thing that's different between Angle and all of the companies that you mentioned, is that they offer services. They do not have an FDA product clearance even for the CtDNA activity. They have service based clearances, which means they can offer a service from a laboratory. What we're doing is we're getting the first FDA product clearance. Which means that we can sell our Parsortix instrument and its consumables to hospitals in the United States for the intended use, and that really opens up a completely different market, because if you provide a product then everybody can use it for a whole variety of different things rather than a service.
So there's a very great distinction between us and the companies you mentioned, but equally we want to work with those companies. We're actively keen to collaborate with them, because the waste products of the CtDNA process is the blood cell components and that includes the circulating tumour cells. So with the same tube of blood from the patient, those companies if they used our products could also offer a lot wider information. So we want to work with them. It would be really complementary and we can add to their existing offerings.”